BioSpace News Archive

B. Braun Interventional Systems Inc. (BIS) announced today that they will collaborate with Infraredx, a Nipro Company, to accelerate the U.S. Food and Drug Administration (FDA) Investigational Device Exemption (IDE) clinical trial for the B. Braun SeQuent® Please ReX™ Drug Coated PTCA Balloon Catheter, which received FDA Breakthrough Device Designation in late 2019

EnGen Bio is an early stage biotechnology company developing a new approach to preventing and treating all Type A influenza strains—including all flu pandemics.

Vocera Communications, Inc. (NYSE:VCRA), a recognized leader in clinical communication and workflow solutions, today announced that it received FIPS 140-2 certification for the Vocera Smartbadge.

TORONTO, March 31, 2021 /PRNewswire/ - Kontrol Technologies Corp. is pleased to provide an update on its manufacturing capacity as it relates to various milestones for the Ontario Together Fund.

BioLargo, Inc., a developer of sustainable cleantech technologies and full-service environmental engineering company, filed its Annual Report on Form 10-K with the SEC for the year ended December 31, 2020.

US Digestive Health, a management services organization established to expand access to high-quality, low-cost gastroenterology care, announced the addition of Brad Stoltz as Chief Operating Officer for the fast-growing organization.

KeifeRx, LLC, an emerging clinical-stage biotechnology company specializing in the discovery and development of new treatment options for neurodegenerative diseases, announced today that Chris Hoyt, former Co-Founder and CFO of Upskill Inc., has been appointed to serve as Chief Executive Officer.

Gracell Biotechnologies Inc. (NASDAQ:GRCL)(“Gracell”), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that the company has entered into a Manufacturing Service Agreement (MSA) with Lonza

Enhancing Care for Children with Asthma project expands to nearly 450 clinics, improving the health and school attendance of more than 1.5 million children with asthma

Yumanity Therapeutics (NASDAQ: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, today announced financial results for the full year ended December 31, 2020 and provided an overview of the Company’s recent corporate developments and upcoming milestones.